March 26, 2018 / 8:08 PM / 4 months ago

BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients

March 26 (Reuters) - Anaptysbio Inc:

* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS

* ANAPTYSBIO INC - ‍ANB020 WAS WELL TOLERATED AND NO PATIENTS HAVE DISCONTINUED FROM STUDY​

* ANAPTYSBIO INC - ‍ANAPTYSBIO PLANS TO INITIATE A MULTI-DOSE PHASE 2B TRIAL IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS​

* ANAPTYSBIO INC - ‍NO SERIOUS ADVERSE EVENTS HAVE BEEN REPORTED FROM STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below